FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome
ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.
ADHD Medications: A Look at Their Safety Profile
Each year in this country, physicians prescribe medications to treat ADHD in nearly 3 million children. The safety of these agents has been the subject of some debate.
Toddler tablet use may hinder attentive, behavioral development
A laboratory-based assessment shows children aged 18 - 32 months old were less likely to listen to attention prompts or their parent's requests when provided an iPad versus a standard toy.
Screening tool identifies kids at high risk for reading disorders
Investigators therefore concluded that ROAR provides an excellent way to identify children at highest risk of having poor reading skills.
Early childhood genetic testing for global developmental delay could reduce misdiagnosis rate
Overall, the findings of the study support the clinical utility of combining trio-WES sequencing with CNV-seq in the etiologic diagnosis and management of early-childhood GDD.
Weekly review: ADHD treatment FDA approval, peanut consumption and adolescent tolerance, and more
Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.